This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.

Inclusion Criteria:

1. Histologically/cytologically confirmed locally advanced or metastatic non squamous NSCLC (AJCC 8th edition Stage IIIB-IV).
2. Confirmed RAS mutation or KRAS amplification；tumor cell PD L1 test report available
3. No prior systemic anti-tumor therapy for advanced disease
4. At least 1 measurable lesion outside the central nervous system (CNS) per RECIST v1.1
5. ECOG performance status 0 or 1
6. Life expectancy\>3 months
7. Willing to provide written informed consent
8. Fertile participants must use effective contraception
9. Adequate organ function

Exclusion Criteria:

1. Other active malignancy within 3 years
2. Symptomatic brain metastases, leptomeningeal disease, spinal cord compression, or primary brain tumor
3. History of active clinically significant cardiovascular dysfunction
4. Known to harbor other targetable driver gene alterations
5. Presence of active infection (HIV, HBV, HCV,)
6. Prior anti-tumor therapy within 28 days or 5 half-lives
7. Diagnosis of unstable thrombotic events requiring therapeutic intervention within 3 months prior to the first dose of study treatment.
8. Hypersensitivity to study drugs, or inability to swallow tablets or comply with study procedures.
9. History of central nervous system (CNS)disease
10. Presence of clinically significant interstitial lung disease, radiation pneumonitis, or immune-related pneumonia that requires treatment.
11. With uncontrollable or symptomatic pleural effusion, ascites, or pericardial effusion.
12. Active autoimmune disease requiring systemic treatment.